Investigator's choice

Phase 3Small molecule

Pfizer

Investigator's choice is one of 132 small molecule programs targeting Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

131

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

MelanomaPhase 3

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Mantle Cell LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

11 2

Alkeran

AApotex Inc.

Phase 3

11 3

Intismeran Autogene

Merck & Co.

Phase 3

1 4

Systemic Chemotherapy

SSun Yat-sen University

Phase 3

1 5

Peg-IFN Alfa-2b

Merck & Co.

Phase 3

1 6

Investigator's choice

Pfizer

Phase 3

1 7

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 8

Intron a

Merck & Co.

Preclinical

4 9

Opdualag

Bristol-Myers Squibb

Preclinical

3 10

IO102-IO103

IIO Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Melanoma

NCT05549297

Q1 2029

Phase 3Recruiting

Head and Neck Squamous Cell Carcinoma

NCT06496178

Clinical

Trials by Indication[1]

Herpes Simplex Virus1 trial

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Completed·AAiCuris Anti-infective Cures AG·Phase 3·NCT03073967·158 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Recruiting·MMerus B.V.·Phase 3·NCT06496178·500 enrolled

Melanoma1 trial

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Recruiting·IImmunocore Ltd·Phase 3·NCT05549297·540 enrolled

Mantle Cell Lymphoma1 trial

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Completed· Pfizer logo

Pfizer·Phase 3·NCT00117598·169 enrolled

Acute Myeloid Leukaemia (AML)1 trial

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

Completed·CClavis Pharma·Phase 3·NCT01147939·381 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Investigator's choice. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigator's choice compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigator's choice. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Investigator's choice

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Trials by Indication[1]

Herpes Simplex Virus1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Melanoma1 trial

Mantle Cell Lymphoma1 trial

Acute Myeloid Leukaemia (AML)1 trial

References

Drug Info

Quick Facts

Related News